Intravitreal Antiangiogenic Therapy of Uveitic Macular Edema: A Review

Igor Kozak, Samir S. Shoughy, Donald U. Stone

Research output: Contribution to journalReview article

Abstract

Uveitic (or inflammatory) macular edema (UME) is one of the most common cause of visual impairment in patients with uveitis and the most frequent structural complication of uveitis. The use of antiangiogenic agents in the management of macular edema due to inflammation is a fairly new approach. It is not entirely clear if these agents should be used as an adjunct to anti-inflammatory therapy or if they can be used as stand-alone agents in edema due to infections where immunosuppressive therapy could be detrimental to the resolution of infection. This treatment paradigm is largely borrowed from large randomized trials in other retinovascular diseases. Similar prospective studies are needed to clarify the role of antiangiogenic therapy in UME.

Original languageEnglish (US)
Pages (from-to)235-239
Number of pages5
JournalJournal of Ocular Pharmacology and Therapeutics
Volume33
Issue number4
DOIs
StatePublished - May 1 2017

Fingerprint

Macular Edema
Uveitis
Angiogenesis Inhibitors
Vision Disorders
Therapeutics
Immunosuppressive Agents
Infection
Edema
Anti-Inflammatory Agents
Prospective Studies
Inflammation

Keywords

  • aflibercept
  • antiangiogenic agents
  • bevacizumab
  • macular edema
  • ranibizumab
  • uveitis

ASJC Scopus subject areas

  • Ophthalmology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Intravitreal Antiangiogenic Therapy of Uveitic Macular Edema : A Review. / Kozak, Igor; Shoughy, Samir S.; Stone, Donald U.

In: Journal of Ocular Pharmacology and Therapeutics, Vol. 33, No. 4, 01.05.2017, p. 235-239.

Research output: Contribution to journalReview article

Kozak, Igor ; Shoughy, Samir S. ; Stone, Donald U. / Intravitreal Antiangiogenic Therapy of Uveitic Macular Edema : A Review. In: Journal of Ocular Pharmacology and Therapeutics. 2017 ; Vol. 33, No. 4. pp. 235-239.
@article{ad5cb7df03e94cbfab8082f44e551a1f,
title = "Intravitreal Antiangiogenic Therapy of Uveitic Macular Edema: A Review",
abstract = "Uveitic (or inflammatory) macular edema (UME) is one of the most common cause of visual impairment in patients with uveitis and the most frequent structural complication of uveitis. The use of antiangiogenic agents in the management of macular edema due to inflammation is a fairly new approach. It is not entirely clear if these agents should be used as an adjunct to anti-inflammatory therapy or if they can be used as stand-alone agents in edema due to infections where immunosuppressive therapy could be detrimental to the resolution of infection. This treatment paradigm is largely borrowed from large randomized trials in other retinovascular diseases. Similar prospective studies are needed to clarify the role of antiangiogenic therapy in UME.",
keywords = "aflibercept, antiangiogenic agents, bevacizumab, macular edema, ranibizumab, uveitis",
author = "Igor Kozak and Shoughy, {Samir S.} and Stone, {Donald U.}",
year = "2017",
month = "5",
day = "1",
doi = "10.1089/jop.2016.0118",
language = "English (US)",
volume = "33",
pages = "235--239",
journal = "Journal of Ocular Pharmacology and Therapeutics",
issn = "1080-7683",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Intravitreal Antiangiogenic Therapy of Uveitic Macular Edema

T2 - A Review

AU - Kozak, Igor

AU - Shoughy, Samir S.

AU - Stone, Donald U.

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Uveitic (or inflammatory) macular edema (UME) is one of the most common cause of visual impairment in patients with uveitis and the most frequent structural complication of uveitis. The use of antiangiogenic agents in the management of macular edema due to inflammation is a fairly new approach. It is not entirely clear if these agents should be used as an adjunct to anti-inflammatory therapy or if they can be used as stand-alone agents in edema due to infections where immunosuppressive therapy could be detrimental to the resolution of infection. This treatment paradigm is largely borrowed from large randomized trials in other retinovascular diseases. Similar prospective studies are needed to clarify the role of antiangiogenic therapy in UME.

AB - Uveitic (or inflammatory) macular edema (UME) is one of the most common cause of visual impairment in patients with uveitis and the most frequent structural complication of uveitis. The use of antiangiogenic agents in the management of macular edema due to inflammation is a fairly new approach. It is not entirely clear if these agents should be used as an adjunct to anti-inflammatory therapy or if they can be used as stand-alone agents in edema due to infections where immunosuppressive therapy could be detrimental to the resolution of infection. This treatment paradigm is largely borrowed from large randomized trials in other retinovascular diseases. Similar prospective studies are needed to clarify the role of antiangiogenic therapy in UME.

KW - aflibercept

KW - antiangiogenic agents

KW - bevacizumab

KW - macular edema

KW - ranibizumab

KW - uveitis

UR - http://www.scopus.com/inward/record.url?scp=85018315983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018315983&partnerID=8YFLogxK

U2 - 10.1089/jop.2016.0118

DO - 10.1089/jop.2016.0118

M3 - Review article

C2 - 28165851

AN - SCOPUS:85018315983

VL - 33

SP - 235

EP - 239

JO - Journal of Ocular Pharmacology and Therapeutics

JF - Journal of Ocular Pharmacology and Therapeutics

SN - 1080-7683

IS - 4

ER -